SynAct Pharma AB is a manufacturer of biological products. The Company is located in Lund, Sweden. It develops medicines for acute impairment in inflammatory diseases. The company's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.

Employees

Sector

Pharmaceuticals

Calendar

11-02 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	SEK 16.22	-3.22%	153,318
29/10/26	SEK 16.76	-4.12%	84,149
28/10/26	SEK 17.48	-2.89%	96,905
27/10/26	SEK 18.00	+0.78%	250,114
26/10/26	SEK 17.86	+3.60%	120,456

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - SynAct Pharma AB

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - SynAct Pharma AB

Company calendar

Market Closed - Nasdaq Stockholm 15:30:00 30/10/2026 +03			5-day change	1st Jan Change
16.22 ^SEK	-3.22%		-5.92%	-28.23%

10-27	Synact Pharma enters commercial agreement with Brazilian company Hipolabor	FW
10-27	SynAct Pharma enters partnership agreement for resomelagon with Brazilian pharmaceutical company	FW

Market Cap	908M 92.46M 82.8M 76.17M 69.01M 129M 8.78B 131M 365M 4.62B 347M 340M 14.56B	P/E 2026 *	-9.65x	P/E 2027 *	-16.6x
Enterprise Value	933M 94.98M 85.07M 78.25M 70.9M 133M 9.02B 135M 375M 4.74B 356M 349M 14.96B	EV / Sales 2026 *	21.1x	EV / Sales 2027 *	45.5x
Free-Float	74.7%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SYNACT	Delayed
CBOE		Real-time
Deutsche Boerse AG	8F8	Delayed
Börse Stuttgart	8F8	Delayed
CBOE		Real-time
Tradegate	8F8	Real-time
Boerse Muenchen	8F8	Real-time

10-27	Synact Pharma enters commercial agreement with Brazilian company Hipolabor	FW
10-27	SynAct Pharma enters partnership agreement for resomelagon with Brazilian pharmaceutical company	FW
10-27	Synact Pharma Signs First Commercial Partnership for Resomelagon with Hipolabor Farmacêutica LTDA	CI
09-16	Synact Pharma's resomelagon highlighted by WHO for dengue fever	FW
09-16	SynAct Pharma Identifies Resomelagon As One Of Six Dengue Drug Candidates With Evidence Supporting Further Clinical Development	CI
09-07	Synact surged in Stockholm, the OMXS30 index rose 0.2 percent	FW
09-07	Rejlers slides on merger plans, OMXS30 index up 0.3 percent	FW
09-07	Synact Pharma sees support for phase 3 after post hoc analysis	FW
09-07	SynAct Pharma AB Announces Further Analysis Of Phase 2b ADVANCE Study And Supports Phase 3 Development For Resomelagon	CI
09-03	Stockholm stocks rise, Clas Ohlson jumps on earnings, OMXS30 index up 0.6 percent	FW
09-03	Synact Pharma CEO and head of research sell shares for tax reasons	FW
08-28	Synact Pharma to present new preclinical data for resomelagon at WCI	FW
08-28	SynAct Pharma Presents New Resomelagon Preclinical Data On Phase 3-Ready Ra Therapeutic Candidate At The 17th World Congress Of Inflammation 2026	CI

SynAct Pharma AB Stock

Stocks

SYNACT

SE0008241491

Pharmaceuticals

Valuation: SynAct Pharma AB

Chart: SynAct Pharma AB

Latest news: SynAct Pharma AB

Last Transcript: SynAct Pharma AB

Analysts' recommendations: SynAct Pharma AB

Press Releases: SynAct Pharma AB

Quotes and Performance

Price Extremes

Managers and Directors: SynAct Pharma AB

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

06-18	Edison Maintains Its Valuation for Synact Pharma After Trial Results	FW
03-04	Edison Raises Valuation of Synact Pharma - Commissioned Analysis	FW
02-09	Redeye Raises Target Price for Synact Pharma to 31 Kronor (26)	FW
31/10/25	Redeye Raises Target Price for Synact Pharma to 26 Kronor (25)	FW
28/10/25	Edison Initiates Coverage of Synact Pharma, Assigns Value of SEK 36.9 Per Share	FW

09-22	SynAct Pharma to participate in investor and partnering conferences	AQ
09-16	WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development	AQ
09-10	SynAct Pharma to Present at Investing in Life Science on September 22	AQ
09-08	SynAct Pharma : Bolagspresentation September 2026	PU
09-08	SynAct Pharma : Company presentation	PU

1 day	-3.22%
1 week	-5.92%
1 month	-5.59%
3 months	-11.17%
6 months	-7.74%
Current year	-28.23%

1 week	15.8	19.8
1 month	15.8	19.8
Current year	7.05	24.4
1 year	7.05	24.5
3 years	4.98	25.3
5 years	4.98	146
10 years	4.8	146

Manager	Title	Age	Since
Jeppe Øvlesen CEO	Chief Executive Officer	64	01/01/2014
Ann Kristin Led DFI	Director of Finance/CFO	-	01/03/2026
Kirsten Harting CTO	Chief Tech/Sci/R&D Officer	-	15/02/2024

Director	Title	Age	Since
Jeppe Øvlesen BRD	Director/Board Member	64	20/03/2024
Anders Kronborg CHM	Chairman	62	20/03/2024
Sten Scheibye BRD	Director/Board Member	75	20/03/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/2/26 A	Jeppe Øvlesen	Sell	Founder	-150,000	0.2813%
9/2/26 A	Thomas Jonassen	Sell	Chief Technology Officer	-350,000	0.6563%
3/10/26 A	Anders Kronborg	Buy	Chairman	2,750	0.0052%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNACT PHARMA AB	-3.22%	-5.92%	-32.98%	+207.78%	92.46M
ELI LILLY AND COMPANY	+3.19%	+11.31%	+64.28%	+155.66%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.65%	+83.74%	658B
ABBVIE INC.	+1.41%	+3.24%	+35.25%	+106.98%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+55.81%	+69.71%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.90%	+45.38%	369B
NOVARTIS AG	+1.12%	+4.52%	+34.76%	+57.00%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.95%	+35.06%	290B
AMGEN INC.	+1.15%	+6.09%	+56.15%	+78.66%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+42.48%	+112.84%	212B
Average	+1.55%	+4.72%	+38.63%	+95.28%	426.2B
Weighted average by Cap.	+2.01%	+6.60%	+50.51%	+99.19%

	2026 *	2027 *
Net sales	44.25M 4.5M 4.03M 3.71M 3.36M 6.28M 428M 6.4M 17.76M 225M 16.9M 16.54M 709M	21.6M 2.2M 1.97M 1.81M 1.64M 3.07M 209M 3.13M 8.67M 110M 8.25M 8.08M 346M
Net income	-47.08M -4.79M -4.29M -3.95M -3.58M -6.69M -455M -6.81M -18.9M -239M -17.99M -17.6M -755M	-31.92M -3.25M -2.91M -2.68M -2.43M -4.53M -309M -4.62M -12.81M -162M -12.19M -11.93M -512M
Net Debt	24.81M 2.53M 2.26M 2.08M 1.89M 3.52M 240M 3.59M 9.96M 126M 9.48M 9.28M 398M	74.22M 7.55M 6.77M 6.22M 5.64M 10.54M 717M 10.74M 29.79M 377M 28.35M 27.75M 1.19B